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1. Introduction 
The progress made in the field of liver organ transplantation has revolutionized the treatment 
of a wide spectrum of liver diseases. Orthotopic liver transplantation (OLT), which requires 
removal of the entire native liver and transplantation of a high quality graft, has become an 
almost routine procedure with 1-year survival rates higher than 80%. However, with the 
ensuing interminable increase in the waiting list, the current major limitation is the 
considerable shortage in organ donors and the need of timely availability of suitable livers. 
As a result, although death rate after surgery is slowly decreasing, the number of total deaths 
in waiting list patients is steadily rising. Several solutions have been proposed to overcome 
this problem, such as legislative measures, mass media campaigns, optimization of available 
organ allocation, or innovative surgical techniques such as split-liver, living donor, non-heart 
beating donor, and domino transplantation. However, these measures have been met with 
only limited success in providing enough liver grafts (Neuberger, 2000; Thalheimer & Capra, 
2002). Hence, the research community endeavoured to establish clinical alternatives to liver 
transplantation. Cell-based therapies are emerging as an alternative to whole-organ 
transplantation, which has shown initial promise in both animal models and clinical cases. 
This novel technique may provide functional liver support while the native liver regenerates 
in patients of acute liver failure, may provide a short-term “bridge” to sustain critical patients 
until OLT, or may aid in replacing a missing enzyme function in metabolic conditions with 
the aim of avoiding OLT. Some of the most promising cells types that could be used in this 
emerging field are hepatocytes, embryonic stem cells (ESC), mesenchymal stromal cells 
(MSC), amnion epithelial (AE) cells, and induced pluripotent stem cells (iPSC).  
2. Cell transplant versus OLT 
Although still in the experimental stages, cell transplant (CTx) has a variety of potential 
advantages over whole liver transplant. OLT requires major invasive surgery associated 
with long recovery times and a high prevalence of post-surgical complications such as 
infections, renal failure, and acute rejection, which could all contribute to patient mortality. 
The financial cost of OLT and subsequent lifelong immunosuppression therapy is substantial,  
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and long term immunosuppression has also been linked to an increased incidence in 
cancers. Finally, the number of livers needed for transplant greatly outnumbers available 
livers, and timing is critical. In contrast, CTx is less invasive, less expensive, and is 
associated with less severe and fewer complications as well as shorter recovery times. 
Theoretically, stable patients, such as those with a metabolic disease, could potentially be 
given an infusion of cells as an outpatient procedure. Cells for transplant can be banked and 
cryopreserved for almost instant availability; therefore, procedural timing would no longer 
be a major concern. One significant benefit of CTx is that patients would retain their native 
liver. This is of particular relevance for patients with metabolic liver diseases. For example, a 
patient with Maple Syrup Urine Disease (MSUD) has a mutation in the enzyme complex 
that catalyzes the permanent degradation of branched-chain amino acids (BCAA), but can 
perform all other necessary liver functions. Therefore, transplanted cells would not need to 
provide complete liver support. In addition, since a metabolic disease patient is not reliant 
on the donor cells for other liver functions, loss of a graft or failure of the cells to perform 
would only return the recipient to pretransplant conditions. Cells can also be infused into 
patients multiple times, and OLT remains an option if CTx proves insufficient. Less 
immunosuppression may also be required, though this would likely depend on the type of 
cells used, the number of cells infused, and each patient’s individual needs. 
3. Cell types, utility for transplant, and major benefits / concerns 
Cell transplant may be clinically useful for cell support for acute liver failure, as a “bridge” 
therapy to whole liver transplantation, or for the treatment of metabolic liver disease (Strom 
& Ellis, 2011). Hepatocytes, as well as many stem or stem-like cells (ESC, MSC, AE, and 
iPSC), are all being investigated for use in this novel yet promising branch of regenerative 
medicine. Each cell type has its own associated risks and benefits, which will be discussed 
separately. 
3.1 Hepatocytes 
The adult human liver consists of approximately 250 billion hepatocytes organized in about 
one million hepatic lobules. Each capillary leads to a lobule. Hepatocytes, the basic 
metabolic cell of the liver, constitute approximately 65–80% of the cell population of the 
liver. These cells are involved in protein synthesis, storage and transformation of 
carbohydrates, synthesis of cholesterol, bile salts and phospholipids, detoxification, and 
modification and excretion of exogenous and endogenous substances (Kaplowitz, 1992). The 
hepatocyte also initiates the formation and secretion of bile. Other important cells of the 
liver include Kupffer cells, stellate cells, and endothelial cells. Kupffer cells are specialized 
macrophages located in the liver that form part of the reticuloendothelial system. Their 
development begins in the bone marrow with the genesis of peripheral blood monocytes, 
and completing their differentiation into Kupffer cells in the liver. The primary functions of 
Kupffer cells are to recycle old and non-functional red blood cells, phagocytosis, and 
clearance of pathogens. Stellate cells, also known as Ito cells, are pericytes found in the 
perisinusoidal space (space of Disse) and represent ~5-8% of the total liver cell number. In 
normal liver, stellate cells are largely quiescent, store vitamin A, and have cell body 
protrusions that wrap around sinusoids. The stellate cell is the major cell type involved in 
liver fibrosis, which is the formation of scar tissue in response to liver damage. When liver is 
damaged, stellate cells can change into an activated state, and are responsible for secreting  
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collagen and other extra-cellular molecules which can lead to cirrhosis. Endothelial cells 
constitute the wall of the liver sinusoids. They lie on a discontinuous extracellular matrix, 
creating a narrow extravascular fluid compartment into which hepatocytes project microvilli. 
This arrangement maximizes the surface area of hepatocytes with the extravascular fluid 
space and permits free movement of solutes into contact with the hepatocyte plasma 
membrane. 
In healthy individuals, regeneration is slow; it is commonly accepted that liver is replaced 
by normal tissue renewal approximately once a year. The liver is largely quiescent with only 
1:1000 hepatocytes in mitosis at any given time. This number decreases with increasing age, 
making regeneration slower and less complete in older animals (Steer, 1995). However, this 
slow cellular turnover is quickly altered when a chemical or physical trauma occurs to cause 
a significant loss to the liver. Sudden and massive hepatocyte proliferation then occurs due 
to a rapid increase in mitotic division resulting in restoration of functional liver mass 
(Bucher, 1963).  
3.1.2 Hepatocyte transplantation and route of administration 
Hepatocytes are capable of rapid proliferation as well as complete and functional 
regeneration of the liver following injury. Thus, this capacity for self-renewal has led some 
to regard the hepatocyte as essentially a “unipotent” stem cell. As early as 1977, hepatocyte 
transplantation (HTx) has been recognized as an attractive option for the management of 
metabolic liver disease (Groth et al., 1977). Groth and colleagues demonstrated that 
intraportal HTx in glucuronosyltransferase-deficient rats improved hyperbilirubinemia. 
Since then, continuing preclinical research determined that HTx can support liver function 
and improve survival in animal models of acute liver failure suggesting it had potential 
clinical application (Gupta & Chowdhury, 2002). There have also been a large number of 
studies with various animal models that show the efficacy of hepatocyte transplantation to 
correct metabolic liver disease (as reviewed in Malhi & Gupta, 2001; Strom et al, 2006). 
Importantly, Harding’s group showed the correction of murine phenylketonuria (PKU) 
despite low engraftment of cells (Hamman et al., 2005); Harding & Gibson (2010) later 
suggest only 10-20% repopulation may be sufficient to correct PKU clinically. Our group 
also recently reported a significant partial correction of murine intermediate MSUD despite 
very low (~3%) repopulation of the liver (Skvorak et al., 2009a; 2009b). As a result, HTx has 
gained attention as a potential therapeutic intervention for a number of liver diseases, and 
transplantation of hepatocytes corresponding to 1-5% of total liver mass (1.5-9.0 billion 
hepatocytes) can be expected to have a positive impact. It has been determined that 
approximately 3.5-7.5% of liver mass can safely be transplanted in one transplant event (Fox 
et al., 1998), whereby the transplant may be divided in up to 6 separate infusions over a 
number of hours. CTx is generally associated with an increase in portal pressures as blood 
flow is restricted by plugs of donor hepatocytes (Gupta et al., 1999). However, if 
transplanted cells are in the range of 5% of the total liver mass, this increased portal 
pressure usually resolves within minutes or hours. When portal pressures return to normal, 
or at least decrease to acceptable levels, it is then safe to infuse more cells. At present, the 
majority of hepatocyte transplant procedures have been performed in adults with acute or 
chronic liver failure, though HTx as a therapeutic alternative to treat metabolic hepatic 
disease is becoming more accepted. Thus far, there have been four reported clinical cases of 
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recovery from acute liver failure following HTx (Table 1), though the use of cell transplant 
as a “bridging” therapy to OLT is more common in both acute and chronic liver failure. 
Most published articles report a positive impact of HTx in clinical studies, and results are in 
general agreement with preclinical data using animal models. Table 1 summarizes clinical 
hepatocyte transplant studies to date, as well as significant results of those studies. 
HTx as an alternative treatment for metabolic liver disease is an appealing proposal. The 
progression of inherited metabolic liver disease usually varies less than cases of liver failure. 
In addition, objective parameters such as laboratory data (i.e. bile acid, clotting factors, etc.) 
can be determined to unequivocally assess the efficacy of the treatment. On the other hand, 
the situation is rarely immediately life threatening and often acceptable conventional 
therapies are available, such as a special diet. Therefore, the potential benefit must be 
carefully weighed against any possible complications, such as immunosuppression, 
embolisation of the pulmonary vascular system, sepsis, or hemodynamic instability. HTx is 
more often done as therapy for inborn errors of hepatic metabolism in which a specific 
absent protein can be measured from transplanted unmodified donor hepatocytes 
expressing the gene. The use of hepatocyte infusions to correct inborn errors of metabolism 
is logical when a specific metabolic deficiency, with well-studied animal modelling, can be 
measured. Then, after infusion of donor liver cells natively expressing the required gene, 
objective measures of required hepatocyte mass, engraftment percent, and survival 
advantage can be obtained. Thus far, therapeutic benefit has been seen clinically in the 
treatment of disorders of the urea cycle (citrullinemia, OTC, argininosuccinase lyase 
deficiency), familial cholesterolemia, Crigler-Najjar, biliary atresia, infantile refsum disease, 
Factor VII, and Glycogen storage disease type 1a & 1b (summarized in Table 1). To avoid the  
need for immunosuppression or the risk of rejection, transplantation of genetically modified 
autologous hepatocytes may also be an option, such as in a clinical study to treat familial 
cholesterolemia (Grossman et al., 1991). In this study, retrovirus was used to transduce and 
correct a patient’s deficient hepatocytes, which were then infused back into the patient to 
yield a partial correction of the disease. HTx to treat progressive familiar intrahepatic 
cholestasis and A1AT were also attempted, but no clinical benefit was determined likely due 
to the presence of fibrosis in the native liver (Strom et al., 1997a; Strom et al., 1999; Hughes 
et al., 2005). With respect to long-term engraftment, it will be important whether the 
transplanted hepatocytes will gain a selection advantage over the recipient’s cells. Damage 
or injury to the native liver triggers rapid proliferation of healthy hepatocytes; theoretically 
this would provide transplanted hepatocytes a selected growth advantage over native cells 
in patients with acute or chronic liver failure. Importantly, the livers of metabolic disease 
patients are not injured or damaged in most cases; transplanted cells would likely not 
receive selection advantage over the recipient’s cells. Therefore, higher numbers of 
transplanted hepatocytes, a need for better cell engraftment, and repeated transplantations 
may be necessary for the successful treatment of metabolic liver diseases.  
Cell therapy of end-stage liver disease (i.e. cirrhotic livers) is more problematic. Infusion 
into the liver via the portal vein is the preferred method of transplant in cases where liver 
architecture is intact (i.e., metabolic diseases, or in the case of acute liver failure). It is known 
from animal studies that hepatocytes infused via the portal vein disperse with the portal 
blood flow and finally translocate to the hepatic sinusoids in the periportal region of the 
liver lobules (Sokal et al., 2003). Single cells succeed in traversing the endothelial barrier and 
integrate into the parenchyma. After re-establishing intercellular contacts with neighbouring  
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Liver Disease  Outcome References 
α1-antitrypsin (A1AT) No clinical benefit likely due to the 
presence of fibrosis 
(Strom et al., 1997a; Strom 
et al., 1999) 
Acute liver failure Reversal of disease  (Fisher et al., 2000; Soriano, 
2002; Fisher & Strom, 2006; 
Ott et al., 2006) 
Argininosuccinate lyase 
deficiency  
Complete correction (Stephenne et al., 2006) 
Biliary atresia Partial correction - slow and 
continuous decrease in bilirubin 
levels 
(Khan et al., 2008) 
Chronic liver failure Bridge to OLT (Bilir et al. 200; Strom et al. 
1997b; Fisher & Strom, 
2006; Strom et al., 1999)  
Citrullinemia Partial correction – decreased 
citrulline and circulating ammonia 
at 6 months post- cell infusion 
(Meyburg et al., 2009a) 
Crigler-Najjar type 1 Partial correction - slow and 
continuous decrease in bilirubin 
levels; evidence of long term 
correction by hepatocyte graft (one 
patient was followed for > 1.5 
years) 
(Fox et al., 1998; Dhawan et 
al., 2004; Ambrosino et al., 
2005) 
Familial 
cholesterolemia 
Partial correction – cholesterol 
decrease and transgenic expression 
>4 months 
(Grossman et al., 1991) * 
Glycogen storage 
disease type 1a & 1b 
Partial correction – patients could 
maintain blood glucose between 
meals as well as higher and 
sustained glucose levels at meals 
(Muraca et al., 2002; Lee et 
al., 2007) 
Infantile refsum disease Partial correction – improved fatty 
acid metabolism, reduced pipecolic 
acid and bile salt levels, improved 
strength and weight gain 
(Sokal et al., 2003)  
Inherited Factor VII 
deficiency 
Partial correction – reduced FVII 
requirement 80%  
(Dhawan et al., 2004) 
Ornithine 
transcarbamylase 
deficiency (OTC) 
Partial correction – ammonia and 
glutamine levels were normalized 
following transplant. Most 
required OLT at a later date. 
(Strom et al., 1997a; Horslen 
et al., 2003; Mitry et al., 
2004; Stephenne et al., 2005; 
Puppi et al., 2008; Meyburg 
et al., 2009a; 2009b) 
Progressive familiar 
intrahepatic cholestasis 
No clinical benefit likely due to the 
presence of fibrosis 
(Hughes et al., 2005) 
* use of genetically modified autologous hepatocytes 
Table 1. Summary of clinical HTx to treat chronic liver failure, acute liver failure, and 
inherited metabolic diseases 
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host cells, transplanted hepatocytes may start to proliferate when sufficient space is made 
for the infused cells. Donor cells and their descendents form gradually increasing clusters, 
thus finally repopulating the recipient liver. However, cirrhotic livers contain abnormalities 
of the hepatic architecture, as well as loss of functional hepatocytes, which contributes to the 
decrease in liver function. In addition, intrahepatic portal venous shunts may prevent an 
efficient exchange between hepatocytes and blood plasma, and cell infusions may cause 
prolonged portal hypertension and embolization in the lung (Strom et al., 1999). Preclinical 
HTx studies conducted on rat cirrhosis models discovered significantly increased 
intrapulmonary translocation of donor cells due to portal shunting (Gupta et al., 1993). Due 
to cirrhotic changes in the liver and associated portal hypertension, the infusion of donor 
hepatocytes into the liver via the portal vein without first restoring the normal liver 
architecture would likely cause serious complications in patients with portal hypertension. 
For safety purposes, transplantation into the spleen is preferable (Strom et al., 1997b; Fisher 
& Strom, 2006). Direct intrasplenic injection produced engraftment that was far superior to 
that obtained using splenic artery infusion and resulted in fewer serious complications 
(Nagata et al.; 2003). However, it is still unknown whether the human spleen is capable of 
accommodating a sufficient number of functional hepatocytes to compensate for the 
cirrhotic liver. For example, alcoholic cirrhotic patients showed only transient clinical 
improvement after treatment by splenic HTx (Strom et al., 1999; Sterling & Fisher, 2001). 
Another strategy that has been getting recent attention is the use of a bioartificial liver (BAL) 
to support metabolic function and regeneration (Koenig et al., 2005; Carpentier et al., 2009). 
Several devices are being tested clinically (as reviewed in Carpentier et al., 2009). However, 
current limitations of BAL devices are cost and, due to the shortage of allogenic hepatocytes, 
their prevalent use of porcine hepatocytes, which carry the risk of infection with porcine 
endogenous retrovirus and anaphylaxis (Chamuleau et al., 2005). Treatment of cirrhotic 
livers by CTx requires extra consideration regarding transplant site, cell number, and overall 
safety of the procedure. The continuing development of BAL is promising, but there are 
more challenges to overcome in this area before these devices can be considered a cost-
effective and safe option for the treatment of liver disease. 
3.1.3 Hepatocyte isolation, culture, and cryopreservation  
The major source of hepatocytes for HTx are livers that were rejected for OLT. Some of the 
most common reasons that procured livers are not used for transplantation are as follows:  
unavailability of a matched recipient, physical damage to the liver, pre-existing liver 
diseases, breach of sterility during the procurement process, high liver fat content (steatosis), 
inappropriate age (too old), or inappropriate warm ischemic time or cold storage time (cold 
ischemia). Though these organs may not be therapeutically useful for OLT, viable cells for 
CTx may still be acquired. 
Hepatocyte isolation was first employed in the late-1960s for rat livers (Howard et al., 1967; 
Berry & Friend, 1969). In 1976, the traditional two-step collagenase perfusion technique was 
developed for rat tissue (Seglan, 1976), which was later adapted for use with human tissue 
(Bojar et al., 1976). Another widely used method, which yields a high number of viable cells 
per gram of whole liver tissue, is the three-step collagenase perfusion technique (Dorko et 
al., 1994; Nakazawa et al., 2002; Mitry et al., 2004; Alexandrova et al.; 2005). More recently, 
the increasing application of these approaches in clinical grade cell therapies require the 
standardization of cell isolation procedures in accordance with GMP conditions (Gramignoli 
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et al., 2011). In general, after collagenase has disassociated the hepatocytes from the 
connective tissue, cells are separated by low speed centrifugation, and the hepatocyte pellets 
are washed with ice-cold buffer solution to purify the cells. The number and quality of the 
isolated hepatocytes vary depending on the composition of perfusion buffer solutions, the 
type and concentration of enzyme, and the type and quality of the tissue source used. 
Further purification of viable cells can be obtained through the use of the Percoll 
centrifugation technique (Olinga et al., 2000), though extensive loss in cell number (20-40% 
cell recovery) is a major disadvantage of this method (Dorko et al., 1994). Cell viability is 
determined using trypan blue exclusion. However, in vitro viability may not reflect good cell 
function in vivo.  
The primary requirement for both short-term and long-term culture of hepatocytes is their 
ability to efficiently attach to the culture plate. The culture dish should be pre-coated with a 
suitable attachment factor such as collagen (type I or IV) or Matrigel, which contains a 
mixture of extracellular matrices (Blaauboer & Paine, 1979; Chen et al., 1998). However, even 
under currently optimal in vitro cell culture conditions, mature human hepatocytes typically 
do not survive or maintain mature functionality for periods longer than 1-2 weeks, 
proliferation is extremely poor, and they appear to de-differentiate and lose hepatic 
potential (Tanaka et al., 2006, Nahmias et al., 2007). 
A shortage of donor liver tissue for the isolation of human hepatocytes necessitates the 
development of improved cryopreservation techniques for long-term storage. There are 
several reports describing various cryopreservation techniques and some of the associated 
complexities of the procedure (Diener et al., 1993; Terry et al., 2005; 2007). Hepatocytes are 
typically cryopreserved in suspension, which can occur immediately following isolation. No 
culture step is needed. The ultimate goal of any improved cryopreservation protocol is to 
minimize sudden intracellular formation of ice crystals that could result in ultrastructural 
damage, and thus maintain cell viability, attachment, and metabolic activity upon thawing. 
Storage time of cryopreserved hepatocytes at temperatures well below −100°C (e.g. liquid 
nitrogen or -140°C freezers) may play an important role in the quality of thawed cells. Cells 
are resuspended in ice-cold media (usually Belzer solution, also known as UW) containing 
cryoprotective agents. UW has been well established in the literature to have the best results 
in terms of viability and recovery. The cryoprotectants used can be permeating (e.g., 
DiMethylSulfoxide (DMSO), glycerol) or non-permeating molecules (e.g., polymers, sugars). 
DMSO is the cryoprotectant of choice because it is permeating and highly soluble. It is able 
to enter cells and reduce injury through reduction of ice crystal formation during freezing. 
DMSO, being a polar solvent, may also stabilize the plasma membrane by electrostatic 
interactions. The concentration of these cryoprotectants, as well as the rate at which they are 
added, final cell density, and freezing rate may also be crucial factors contributing to 
viability upon thawing. The standard optimum thawing protocol for hepatocytes is rapid 
thawing at 37°C with slow dilution of the cryoprotectant (to reduce osmotic imbalances) at 
4°C (to reduce possible toxicity of the cryoprotectant) (Karlsson et al., 1993; 1996; Pegg, 
2002). Upon thawing, cells are then washed to remove cryoprotectant to avoid potential 
adverse affects in patients.  
3.1.4 Benefits / concerns 
Due to the undeniable success of OLT, it is reasonable to use all suitable donor livers for 
organ transplantation. Therefore, an advantage of HTx is that it would not require obtaining 
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livers that could be used for OLT, which would only further stress an already stressed 
system. HTx would be using liver tissue that would otherwise be discarded. In addition, 
multiple patients could be treated with hepatocytes from a single tissue donor, and 
potentially, in cases of metabolic disease, a patient’s autologous hepatocytes could be 
collected, genetically manipulated to correct the deficiency, and infused back into the 
patient. Nonetheless, there are still many problems associated with the use of hepatocytes. 
Despite the use of discarded tissue, the current major limitation is the availability of human 
hepatocytes. Although hepatocytes in vivo have remarkable proliferation potential, primary 
hepatocytes proliferate very poorly in vitro, appear to de-differentiate and lose their hepatic 
potential, and display very limited survival (Tanaka et al., 2006, Nahmias et al., 2007). 
Therefore, the collection of hepatocytes for HTx is still limited by the availability of fresh 
liver tissue as cells cannot be expanded in culture. The numbers and/or quality of 
hepatocytes isolated from non-transplantable livers will not allow a widespread application 
of HTx. A second major limitation is the need for timely availability of hepatocytes. If 
hepatocytes cannot be successfully cryopreserved and thawed, some advantages of CTx 
over OLT are lost. Successful cryopreservation is needed for establishment of cell banks, 
which would allow cryopreserved hepatocytes to be available for emergency use in acute 
and chronic liver diseases, or for planned or repeated use in patients with liver-based 
metabolic disorders. A third major limitation is the consistently poor quality of cells after 
cryopreservation. Hepatocytes are very sensitive to freezing damage, and three distinct 
modes of cell death have been identified: cell rupture by the formation of ice crystals, 
necrosis, and apoptosis (Baust, 2002). Loss of membrane integrity, and thus leakage of 
important enzymes and cofactors which affect liver function, low attachment efficiency, and 
a loss in viability of 50% or greater is typical. This situation will remain unaltered until 
alternatives to primary hepatocytes becomes available, which are discussed in the next 
sections of this chapter, or more efficient methods of cryopreservation and storage of 
hepatocytes, as well as cell recovery from cryopreservation are determined.  
3.2 Embryonic stem cells 
Embryonic stem cells (ESC) are derived from totipotent cells of the inner cell mass of the 
blastocyst, an early stage of the developing embryo (Thomson et al., 1998). ESCs are 
pluripotent, meaning they can differentiate into all three germ layers (ectoderm, mesoderm, 
and endoderm), and express many specific gene factors that have come to be known as cell 
markers of pluripotency. Common markers of “stemness” include stage specific embryonic 
antigens (SSEA) 3 & 4, and the tumor rejection antigens (TRA) 1-60 & 1-81 (Thomson et al., 
1998), while some common molecular markers include OCT-4, SOX-2, and Nanog, as well as 
high expression of telomerase reverse transcriptase (TERT) (Thomson et al., 1998; Chambers 
et al., 2003). Telomerase maintains telomere length and adds telomere repeats to 
chromosome ends, which is important in a cell’s replicative lifespan (Vaziri & Benchimol, 
1998). However, high levels of telomerase activity are also found in 80-90% of human tumor 
samples (Chen & Chen, 2011). ESCs will readily become tumorigenic in vivo when injected 
into severe combined immunodeficient (SCID) mice forming either teratomas, tumors 
comprised of cells from all three germ layers, or teratocarcinomas, which are more 
aggressive, malignant teratomas (Ben-David & Benvenisty, 2011). In fact, teratoma 
formation is so characteristic of ESCs, it has become one of the most informative tests of 
pluripotency for ESC-like cells, such as induced pluripotent stem cells (iPSC). ESCs also 
display genetic instability (i.e. aneuplody) in vitro, another unfortunate characteristic they 
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share with cancer cells (Spits et al., 2008). Furthermore, ESCs express very low human 
leukocyte antigen (HLA) class I antigens (Baroja et al., 2004), and almost undetectable levels 
of HLA class II antigens and co-stimulatory factors (Drukker et al., 2006). ESCs are still 
subject to immune system targeting, however. Low expression of HLA class I molecules is 
sufficient to induce acute rejection through the action of cytotoxic T-cells and affect 
treatment tolerance (Robertson et al., 2007; Drukker et al., 2006), which suggests that 
immunosuppression would still be required if patients recieved stem cell-derived CTx. 
Sustaining pluripotency in vitro requires continued expression of Nanog and OCT-4 
(Chambers et al., 2003). The expression of these factors are maintained through co-culture 
with a feeder cell layer, most commonly mouse embryonic fibroblasts (MEFs), and either the 
addition of basic fibroblast growth factor (bFGF) for human ESC, or leukemia inhibitory 
factor (LIF) for mouse ESC. Without optimal culture conditions, ESC will rapidly and 
spontaneously differentiate into cells from all three germ layers (Chambers et al., 2003). 
Finally, ESCs are indefinitely self-renewing theoretically providing an unlimited therapeutic 
source of cells for regenerative medicine (Thomson et al., 1998).  
3.2.1 Inducing hepatic differentiation in ESC and laboratory / clinical data 
ESCs will spontaneously differentiate simply by removing factors and/or allowing the 
formation of spheroid clumps known as embryoid bodies (EB) in culture. ESCs can also be 
made to differentiate along a defined lineage through exposure to specific growth factors. In 
a developing embryo, signals from the cardiac mesoderm and septum transversum 
mesenchyme specify endoderm to accept a hepatic fate. It was eventually determined that 
FGFs and bone morphogenic proteins (BMPs) can mimic the appropriate signals and thus 
induce endoderm towards a hepatic fate (Jung et al., 1999). From there, targets of BMPs and 
FGFs, as well as other in vivo hepatic regulatory genes, such as FoxA genes and the GATA 
and hepatocyte nuclear factor (HNF) transcription factors, defined additional molecules 
tested in differentiation studies to produce hepatocyte-like cells from ESC. Currently there 
are many published protocols to differentiate ESC into various cell types from all three germ 
layers, which have been reviewed elsewhere (Trounson, 2006; Zaret & Grompe, 2008; Soto-
Gutierrez et al., 2008; Sancho-Bru et al., 2009). Hepatocyte-like cells that express α-
fetoprotein (AFP), albumin, cytochrome P450 (CYP450), cytokeratin (CK) 18, and display 
epithelial-like morphology have all been extensively described. However, expression of 
these few factors does not guarantee the differentiated stem cell is a “hepatocyte”; 
hepatocyte-like stem cells may express a few hepatic genes, but they could also be negative 
for many others important to hepatic function (Soto-Gutierrez et al., 2008). In addition, some 
of these hepatic markers are not limited to hepatocyte expression, such as CYP450. 
Therefore, there must be a more stringent check list to determine when a stem cell is 
considered to be completely differentiated.  
There have been many articles describing ESC derived hepatocyte-like cells transplanted 
into liver-damaged mice (e.g. review by Banas et al. 2007) but few have determined the cells 
significantly contribute to improved liver function and regeneration. Induction rates remain 
low regardless of the method used, and general hepatic function of the cells, even once 
transplanted, were very limited when compared to mature hepatocytes (Sharma et al., 2008). 
However, a successful report described ESCs demonstrating liver function able to overcome 
liver damage in mice (Heo et al., 2006). This is encouraging for the field of liver disease, but 
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more efficient differentiation and transplantation techniques must be established. Clinical 
ESC therapy for liver disease is not currently realistic, but at present there are four ongoing 
ESC clinical trials targeting other organs in the United States (Trounson et al., 2011). Two 
trials are in Phase I and are targeting spinal cord injuries or spinal muscular atrophy, while 
the remaining two are in Phase I/II and are targeting Macular Degeneration. All trials 
involve ESCs that were first differentiated in culture prior to transplantation. 
3.3 Mesenchymal stromal cells 
Mesenchymal stromal cells (MSC), formerly known as mesenchymal stem cells, are 
multipotent non-hematopoietic adult stem cells that have been isolated from a variety of 
tissues, including bone marrow, adipose tissue, Wharton’s jelly, umbilical cord blood, and 
different compartments of the placenta (Parolini et al., 2008). Since they originate from 
mesoderm, MSCs show in vitro differentiation potential into three cell lineages (adipogenic, 
chondrogenic, and osteogenic). These cells are highly proliferative fibroblast-like cells that 
display plastic adherence in culture and express specific surface markers (i.e. positive for 
CD105/CD90/CD73, and negative for CD34/CD45/CD11b, or CD14/CD19, or 
CD79α/HLA-DR1) (Dominici et al., 2006). Importantly, MSCs are TERT-negative 
(Zimmerman et al., 2003). Although tumorigenicity is lower than ESC, MSCs have been 
shown to assist tumor growth by transformation and suppression of the antitumor immune 
response (Ren et al., 2009). 
Similar to ESCs, MSCs display reduced immunogenicity, but MSCs also demonstrate a 
powerful immunomodulatory response in vivo (Hematti, 2008; Bifari et al., 2010). MSCs 
interfere with antigen-presenting cells and suppress B-cell differentiation causing inhibition 
of Natural Killer (NK) cells and cytotoxic T cells. They also express a broad number of anti-
inflammatory factors, such as a variety of cytokines and chemokines (Banas et al.; 2008). 
MSCs also inhibit local and systemic proinflammatory responses through inhibition of  
TNF-α and interleukin (IL)-1, which functions to prevent tissue damage (Lin et al., 2011), 
and can nonspecifically inhibit allogeneic lymphocyte proliferation. In addition, MSCs 
express low levels of HLA class I antigens and lymphocyte function-associating antigen 
(LFA)-3, and do not express HLA class II antigens or many co-stimulatory molecules which 
could function to upregulate HLA class II antigens in vivo (Bifari et al., 2010). By far, the 
most exciting and potentially useful characteristics of these cells are their immunomodulatory 
behaviors. MSCs significantly lower the incidence of graft-versus-host disease, autoimmune 
diseases, and can induce tolerance upon transplantation (Le Blanc et al, 2004; 2005; 2007). 
Nonetheless, it should be noted that MSC therapy may also increase the vulnerability to 
viral infections such as herpes (Sundin et al., 2006). 
3.3.1 Differentiation of MSCs and laboratory / clinical data 
Similar to ESC, MSCs are able to differentiate into various cell types by stimulation with 
specific growth factors, and there are many published protocols for differentiating MSCs 
along various cell lineages. For example, a recent review describes a number of protocols for 
differentiating along a hepatic lineage (Puglisi et al., 2011). The ability of MSCs to 
differentiate into hepatocyte-like cells was first reported in 2002 (Schwartz et al., 2002). The 
resulting hepatocyte-like cells performed hepatic functions such as albumin production, 
urea synthesis, glycogen storage, and low-density lipoprotein uptake (Jiang et al., 2002). 
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MSCs are able to differentiate into hepatocyte-like cells by stimulation with hepatocyte 
growth factor (HGF), epidermal growth factor (EGF), and FGF (Lange et al., 2005). MSC-
derived hepatocytes were able to engraft in the liver upon transplantation and have been 
shown to contribute towards improved hepatic function and regeneration (Kuo et al., 2008). 
Conversely, another report using bone marrow MSCs significantly increased the number of 
hepatic stellate cells and myofibroblasts, which could contribute to the fibrotic cascade 
(Russo et al., 2006). Despite the availability of many hepatic differentiation protocols, it is 
currently unclear whether MSCs are able to become hepatic cells through differentiation or 
by cell fusion, as evidenced by Sharma, et al. (2005). In addition, the homing mechanism by 
which intravenously injected MSCs can preferentially recruit to the injured liver is 
interesting (Sakaida et al., 2004), but also not well understood. MSCs preferentially target 
tissues undergoing remodeling; it has been suggested that inflammation might provide key 
regulatory factors in the targeted migration of MSCs into the diseased location (Kuo et al., 
2008).  
Due to their impressive immunomodulatory features, MSCs have been used to treat acute 
graft-versus-host disease and osteogenesis imperfecta in children (Le Blanc et al., 2005). 
MSCs also secrete several factors able to suppress hepatocyte apoptosis, inflammatory 
responses, and liver fibrosis, as well as stimulate hepatocyte proliferation and function (Lin 
et al., 2011; Zhou et al., 2009). Many such factors, for example HGF, can also aid in liver 
regeneration. Preclinical and clinical studies have suggested that MSC transplantation can 
moderately restore liver function and enhance survival rates in fulminant hepatic failure 
and end-stage liver disease (Yagi et al., 2009; Kuo et al., 2008; Banas et al., 2009), though it 
has been suggested that the benefits MSCs provide to damaged livers have more to do with 
the expression of immunomodulatory factors than engraftment and subsequent hepatic 
function of the transplanted cells (Banas et al., 2008). There is little evidence to date that 
verifies whether MSCs are able to form mature hepatocytes, either in culture or once 
transplanted. However, growing evidence does suggest that MSCs may improve cirrhotic 
liver function once infused into patients. For example, bone marrow MSCs transplantation 
reduced liver fibrosis, and improved liver function and survival in mice (Sakaida et al., 
2004) and rats (Abdel Aziz et al., 2007). This provided rationale for the use of autologous 
bone marrow MCSs for cell therapy to treat cirrhosis, which spurred several clinical trials 
investigating cell safety and feasibility (Kharaziha et al., 2009; Mohamadnejad et al., 2007; 
Salama et al., 2010). At present, there are 123 ongoing clinical trials involving MSCs 
investigating a variety of applications including bone, cartilage, and heart repair, immune 
rejection and autoimmune diseases, as well as treatment for cancer, gastrointestinal, and 
neurodegenerative diseases (Trounson et al., 2011). 
3.4 Benefits / concerns of ESCs and MSCs 
Since ESCs possess the ability of unlimited self-renewal, this relieves some pressure to 
identify new cell sources for regenerative medicine. However, although self-renewal is 
generally viewed as a powerful benefit, it is also a double-edged sword. Self-renewal, 
genetic instability, and tumorigenicity are characteristics shared by ESCs and cancer cells. In 
both differentiated and undifferentiated ESCs, there is a risk of malignancy due to their 
associated tumorigenicity and genetic instability (Stutchfield et al., 2010). The generation of 
spontaneous tumors is of particular concern for clinical applications, and much of the 
current research is dedicated to reducing and eventually overcoming this risk. Perhaps with 
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more complete differentiation protocols, this will become a concern of the past. In addition 
to safety issues, ESCs also carry religious, political, and ethical concerns, and there is 
legislation restricting or banning their use in certain countries, such as the United States and 
United Kingdom. In contrast to ESCs, MSCs have fewer ethical concerns, as these cells are 
easily accessible from a variety of postnatal tissues. They exhibit a lower risk of spontaneous 
tumors, and their impressive ability to hide from and modulate the immune response is of 
considerable interest. However, MSCs have been shown to contribute to tumor growth in 
vivo and increased risk of viral infections. Therefore, high-risk patients may not be feasible 
candidates for MSC transplantation.  
Despite many promising therapeutic reports in the literature stating stem cells are able to 
contribute to liver regeneration, particularly with MSCs, there are still many problems 
associated with their use. Even with the considerable number of differentiation protocols 
available to produce various cell types, differentiation methods have not been optimized. 
Though stem cells are abundantly proliferative, high induction rates of hepatic cells are 
currently not possible to provide the required number of cells for transplantation to treat 
disorders of the liver, an organ which contains several billion cells. Furthermore, 
differentiated cells display minimal hepatocyte function both in vitro and in vivo. Once 
transplanted, engraftment is very low with low contributions towards tissue regeneration. 
For these reasons, it is relatively unknown whether stem cell-derived hepatocyte-like cells 
will be useful to treat and correct liver disease. More research is required to determine more 
efficient ways to induce hepatocyte-like cells, and a standardized list of requirements should 
be established to verify complete differentiation. In brief, stem cell derived hepatocyte-like 
cells should demonstrate characteristic hepatic gene expression and function, express 
appropriate transport proteins and transcription factors, metabolize ammonia and 
billirubin, produce albumin and/or bile acids, and no longer express genes characteristic of 
ESC or other cell types. Therapeutically useful hepatocyte-like cells must be safe (i.e. 
nontumorigenic), contribute to liver function in vivo, and importantly, must express hepatic 
genes at a level comparable to mature hepatocytes.  Currently there are no definitive reports 
of any stem cell-derived hepatocytes with these ideal characteristics. 
3.5 Human placenta as a source for stem cells 
The human full term placenta is comprised of three distinct layers: amnion, chorion, and 
decidua (Figure 1). The amnion and chorion are fetal-derived while the decidua originates 
from maternal tissue. The trophoblast layer gives rise to the chorion; the amnion is derived 
from the pluripotent epiblast, which also gives rise to all three germ layers of the embryo. 
The amnion layer is established as early as day 8 following fertilization, well before 
gastrulation when cell fate is specified (day 15-17). The amnion is derived at a time when the 
epiblast remains pluripotent, and amnion epithelial (AE) cells retain some of these 
characteristics. AE cells are easily isolated from full term placenta following live birth, 
which would normally be discarded after delivery. Placenta is readily available and easily 
procured without invasive procedures or causing harm to either mother or baby. In 2007, 
there were 1.4 million cesarean births in the United States, which equates to ~32% of all U.S. 
births (Hamilton et al., 2009). Placentas for cell isolation are typically obtained from cesarean 
deliveries due to sterility concerns; however, all placentas should be considered a useful 
source for stem cells. Theoretically, placental stem cells could be isolated from all term births 
and cryopreserved in a cell bank for future use. Since it has been estimated that as little as 30  
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stem cell lines would be needed to match HLA haplotypes in >80% of the Japanese 
population (Nakatsuji et al., 2008), global banking of placental stem cells containing all HLA 
haplotypes worldwide may be considered a realistic and attainable goal. Therefore, 
placental amnion may provide a useful source of pluripotent stem cells that are plentiful 
and free from most ethical, religious, or political concerns. 
3.5.1 Amnion epithelial (AE) cells 
The amniotic layer is composed of a single-celled epithelial layer of cuboidal and columnar 
cells and a deeper mesodermal layer composed of an upper compact acellular layer and a 
lower fibroblast-containing layer (Figure 1). The epithelial layer of the amnion is in contact 
with the amniotic fluid, which serves to protect and cushion the fetus through gestation. The 
chorionic layer is comprised of a mesodermal layer and an extravillious trophoblast layer. 
The maternally derived decidua, which interacts with the fetal derived trophoblast, serves 
to support the fetus through gas, nutrition, and waste exchange, and protect the fetus from 
the maternal immune system. 
 
AE 
 
AM 
 
 
 
 
 
CM 
 
 
 
 
 
CT 
 
 
 
Decidua
& CT 
Fig. 1. Cross-sectional representation of the human placenta. The amnion and chorion are 
fetal-derived membranes while the decidual membrane is maternally-derived. The amniotic 
layer is composed of a single-celled epithelial layer and a deeper mesodermal layer. The 
chorionic layer is comprised of a mesodermal layer and a trophoblast layer. The maternal 
decidua is intermingled with the fetal chorionic trophoblast. (AE: amniotic epithelium;  
AM: amniotic mesoderm; CM: chorionic mesoderm; CT: chorionic trophoblast.) 
AE cells in culture express stem cell surface markers (e.g. SSEA-3 & 4, TRA 1-60 & 1-81) as 
well as molecular markers of stem cells (e.g. OCT-4, Nanog, SOX-2, FGF-4, and Rex-1), and 
unlike ESC, do not require feeder cell layers to maintain OCT-4 and Nanog expression (Miki 
et al., 2005; Miki & Strom, 2006). Interestingly, AE cells do not express the stem cell marker 
TERT (Miki et al., 2005). Telomerase activity is found in human ESC, multipotent adult  
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progenitor stem cells, human germ cells, and 80-90% of human tumor samples (Chen & 
Chen, 2011). Telomerase-positive stem cells display an unstable karyotype and can become 
tumorigenic, most commonly forming teratomas, when transplanted into SCID mice. 
Conversely, AE cells consistently display a normal karyotype and are nontumorigenic when 
transplanted into SCID mice (Miki & Strom, 2006; Marongiu et al., 2011). In addition, AE 
cells are derived from neonatal tissue and should therefore naturally possess less 
environmental and age-acquired DNA damage (Miki, 2011). It is commonly known in the 
field that amnion does not express HLA class II antigens and only expresses class I antigens 
at low levels, which later led to the premise that AE would be able to bypass the immune 
system. AE cells were also found to secrete anti-inflammatory and immunosuppressive 
factors, which inhibited inflammation and reduced the proliferation of T- and B-cells in vitro 
(Li et al., 2005). Volunteers transplanted with AE cells did not experience any immunological 
reaction, and to date no tumors have ever formed as a result (Akle et al., 1981; Yeager et al, 
1985; Scaggiante et al, 1987; Sakurgawa et al., 1992). Many of these characteristics identify 
AE cells as similar to ESC, but not identical.  
3.5.2 AE cell isolation and differentiation methods 
Placental tissues are obtained with local Institutional Review Board (IRB) approval in the 
U.S., or under appropriate Ethical Committee approval, as well as patient approval. The 
amnion membrane is easily stripped from the underlying layers of the placenta by carefully 
peeling it away from the chorion (Figure 2). The amnion membrane contains AE cells and 
amniotic mesenchymal (AM) fibroblasts. AE and AM cells can be isolated from the amnion 
membrane following simple protocols (Miki et al., 2010; Marongiu, 2010). In brief, for 
collection of AE, the amnion membrane is first washed several times to remove blood 
contamination. The membrane is then subjected to several trypsinization steps, which 
releases the AE cells from the amnion mesenchymal fibroblasts and the connective tissue. 
The trypsin digests are then centrifuged to pellet the AE cells and resuspended in standard  
 
Fig. 2. Isolation of the amnion membrane from the chorion of the placenta. The maternal 
side of the placenta is placed face down and a shallow X-shaped incision (dashed lines) is 
made through the center of the placenta. The thin, nearly transparent amnion membrane is 
then peeled from the chorion starting at the center of the cut and progressing outward 
(direction of the arrow) 
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culture medium. A density separation step is done to enrich the population of SSEA-4 
positive AE cells similar to the process used for hepatocytes. Cell viability is determined by 
trypan blue exclusion and counted with a hemocytometer. An estimated AE cell yield from 
one term placenta is 80-300 million cells (Miki et al.; 2010). When AE cells are cultured in the 
presence of epidermal growth factor (EGF), they readily proliferate with numerous mitotic 
events (Terada et al., 2000), though senescence routinely occurs after 6-10 passages (Miki & 
Strom, 2006).  
AE cells have previously shown the potential to differentiate into all three germ layers in 
vitro (Miki et al., 2005). Similar to ESC, differentiation of AE cells to other cell types is 
dependent upon the culture substrate, as well as which growth factors are added and at 
what concentration (Parolini et al., 2007; Miki, 2011). Our group previously published 
efficient methods to differentiate AE cells along a hepatic lineage (Miki, et al., 2009; 
Marongiu, et al., 2011); after differentiation, AE cells expressed many endodermal/hepatic 
marker genes such as A1AT, hepatocyte nuclear factor-4 (HNF4-α), albumin, CAAT 
enhancer binding protein-alpha (C/EBP-α), many CYP450 genes, CK 8, 18, and 19, CYP7A1, 
plus several others at the level of fetal hepatocytes. Interestingly, cultured AE hepatocyte-
like cells express both CYP3A7 and CYP3A4, which indicates that AE differentiates along a 
pathway similar to human fetal liver. Furthermore, the ratio of CYP3A4 to CYP3A7 implies 
that cells are progressing towards mature hepatocytes (Miki et al., 2009). Early studies 
demonstrated proof of principle for AE cell transplantation through the production of 
dopamine-expressing cells from AE, which could survive and function in a rat model of 
Parkinson’s disease (Kakishita et al, 2000; 2003). Importantly, it was found that when 
undifferentiated AE cells were transplanted into the livers of immunodeficient mice, cells 
displaying hepatic morphology were observed that expressed mature liver genes such as 
transporters, cytochromes, and albumin or A1AT; circulating A1AT was also detected in 
transplanted mice confirming functional engraftment (Miki & Strom, 2006; Marongiu et al.; 
2011).  
3.5.3 AE cell transplantation  
Amnion epithelial cells, due to their stem cell-like pluripotent characteristics, low 
immunogenicity, and anti-inflammatory properties, show exciting promise in the field of 
regenerative medicine. Recently, studies have shown lung protection following human AE 
cell transplantation in a SCID mouse model of bleomycin-induced lung injury (Moodley et 
al., 2010; Murphy et al., 2010). Studies have also shown the efficacy of AE cells on corneal 
resurfacing in horses (Plummer, 2009), rabbits (Wan et al., 2011), and humans patients 
(Nubile et al., 2011), in which amniotic membranes were transplanted as a graft over the 
injury site. These studies were done without immunosuppression and without evidence of 
acute rejection. Differentiated AE have also been used to treat a rat model of Parkinson’s 
disease (Kakishita et al, 2000; 2003). Important for the treatment of liver diseases by CTx, AE 
cells demonstrate hepatic gene expression and functions at a level of mature hepatocytes 
following implantation into the livers of SCID mice, which suggest they differentiate into 
hepatocyte-like cells once engrafted in the liver parenchyma (Miki & Strom, 2006; Marongiu 
et al., 2011). Undifferentiated AE cells were able to functionally engraft into the livers of 
immunocompromised mouse models of liver damage resulting in a reduction of hepatic 
fibrosis, inflammation, and hepatocyte apoptosis (Manuelpillai et al., 2010; Marongiu et al., 
2011). In addition, AE cells have also been used in clinics to correct lysosomal storage 
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diseases with no adverse effects (Yeager et al, 1985; Scaggiante et al, 1987; Sakurgawa et al., 
1992). Finally, our group recently determined that AE cells could partially rescue a mouse 
model of intermediate MSUD (Skvorak et al., 2010), an inborn error of metabolism 
characterized by deficiency of the branched-chain keto-acid dehhydrogenase (BCKDH) 
enzyme complex and high levels of BCAA (Homanics et al., 2006). iMSUD mice were given 
multiple infusions of undifferentiated AE cells, either freshly isolated or cryopreserved, 
directly into the liver parenchyma. AE cell transplantation partially corrected iMSUD mice 
similarly to the partial correction previously obtained with hepatocyte transplantation 
(Skvorak et al, 2009a; 2009b). While untreated iMSUD mice grew sickly and all died prior to 
27 days of age, iMSUD-treated mice displayed improved BCKDH enzyme activity, reduced 
BCAA and other relevant metabolites in the brain and blood, their body weight mimicked 
that of healthy wildtype littermates, and >70% of animals survived to day of life 100 
(Skvorak et al., 2010). Immunosuppression was not used and there was no evidence of 
rejection. 
3.5.4 Benefits / concerns of AE cells 
Current research suggests that stem cells isolated from discarded placenta may be an 
abundant, noncontroversial, and safe source of cells for regenerative medicine. There are a 
multitude of reports in the literature, some going as far back as 1947, which describe the 
successful use of AE and amniotic membranes to treat a variety of disorders both 
preclinically and clinically. Furthermore, isolation is relatively easy, and does not require a 
special laboratory set up (Miki et al., 2007). An average of 100 million cells can be isolated 
from a single term placenta, and AE is able to proliferate robustly in culture; Miki, et al. 
(2005) estimates that 100 million AE cells could be expanded to 10-60 billion cells within six 
passages. Unlike hepatocytes, AE cell viability and morphology are also very stable when 
cryopreserved long term at -80°C. Taken together, these benefits greatly encourage the 
establishment of a placental cell bank. Current umbilical cord blood stem cell guidelines 
could be used as a template to set up similar procurement and banking procedures for 
placental-derived stem cells (Serrano-Delgado et al., 2009).  
AE cells meet many important criteria for clinically relevant cells: expression of anti-
inflammatory factors, nonimmunogenic, maintains a stable karyotype, and consistently 
nontumorigenic in vivo in both SCID mice and humans. Undifferentiated AE cells are 
proposed to become hepatocyte-like once engrafted in the liver parenchyma and have 
contributed to liver function in animal models of disease. There are also many published 
differentiation protocols describing induction along many cell lineages, including hepatic. 
However, though these cells exhibit many advantages, particularly over other stem cell 
types, the ability to produce therapeutically useful cells to treat liver diseases has still not 
been developed from AE cells. Though it is unknown whether differentiation prior to 
transplantation will be necessary, one should assume that differentiation into the required 
cell type will be the most clinically efficient and effective method of treatment. Therefore, 
hepatocyte-like cells derived from AE should be held to the same standardized list of 
requirements, outlined in Section 3.4, as cells differentiated from other classifications of stem 
cells. As with other types of stem cells, more research is required to establish better 
induction of therapeutically useful cells. However, the safety of these cells has been 
exhaustively established and they already have a long history of clinical use. Clinical 
application of AE for liver and other diseases may be in our near future.  
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3.6 Discovery and characterization of induced pluripotent stem cells (iPSC)  
Once an embryo reaches the blastocyst stage, highly specific (i.e. spatially and temporally 
controlled) molecular signaling events coordinate directed differentiation of cells to their 
appropriate cell fate. Therefore, a cell becomes specified not by changing its DNA sequence, 
but by controlling the expression of certain genes through specific signals. The first attempt 
to manipulate a cell’s developmental potential was known as somatic cell nuclear transfer, 
which led to the birth of live lambs (Wilmut et al., 1997). “Dolly” the sheep provided 
evidence that differentiation of a cell towards a somatic state is not accomplished by 
irreversible genetic manipulation.  
Almost a decade later, Yamanaka’s group successfully derived pluripotent ESC-like cells 
from murine somatic cells through forced expression of the reprogramming factors OCT-
3/4, SOX-2, c-MYC, and KLF-4 by lentiviral induction (Takahashi & Yamanaka, 2006). These 
“induced pluripotent stem cells” (iPSC) were similar to ESCs in morphology, growth 
properties, expression of ESC marker genes, display of an unstable karyotype, 
tumorigenicity and teratoma formation in SCID mice, and injection into a blastocyst yielded 
cells that contributed to mouse development. Human iPSC from adult skin fibroblasts were 
also generated using the same four factors as mice (Takahashi et al., 2007), and also by 
forced expression of a new set of four factors: OCT-4, SOX-2, Nanog, and Lin-28 (Yu et al., 
2007). Pluripotent iPSC should express the stem cell markers SSEA3, SSEA-4, TRA-1-60, 
TRA-1-81, OCT-4, alkaline phosphatase, TERT, SOX-2 and Nanog, and form teratomas in 
vivo. It has also been reported that a specific expression profile of stem cell markers 
corresponds to either a completely or partially reprogrammed cell (Chan et al., 2009). 
Recently, iPSCs have been derived from a variety of human tissues, such as umbilical cord 
matrix (Cai et al., 2010), fetal and juvenile tissues (Park et al., 2008a; Li et al., 2010; Aasen et 
al., 2008), placental tissue (Nagata et al., 2009; Cai et al., 2010; Zhao et al., 2010), and primary 
human hepatocytes. However, evidence that iPSC retain epigenetic memory of their cells of 
origin exist for both mouse (Kim et al., 2010; Polo et al., 2010) and human (Hu et al., 2010), 
which can affect their differentiation potential. This is a concern, but it also suggests that the 
best cell source to generate iPSC for the treatment of liver disease would be hepatocytes; 
hepatic-like cells differentiated from hepatocyte-derived iPSC would most closely resemble 
their primary cell counterparts. 
Currently, iPSC research is largely dedicated to reducing the tumorigenicity of the cells. The 
use of retroviruses and lentiviruses is a concern, which integrates into the target cell genome 
in a random fashion potentially causing cancer. The generation of mouse iPSC through the 
use of non-integrating adenoviruses (Stadtfeld et al., 2008) determined reprogramming 
could be achieved through transient expression. Vector integration-free human iPSCs have 
since been derived using Epstein-Barr virus-derived episomes (Yu et al., 2009), mRNA 
transfection (Yakubov et al., 2010), bacterial DNA-free episomal vectors (Jia et al., 2010), and 
proteins (Kim et al., 2009). However, viral integration is only one problem contributing to 
the tumorigenicity of iPSC. c-MYC is a well established oncogene, and the remaining factors 
(OCT-4, SOX-2, KLF-4) are also known to be highly expressed in cancers (Schoenhals et al., 
2009). Recent studies have shown that reprogramming could be successful without using c-
MYC and KLF-4 (Li et al., 2010; Huangfu et al., 2008). However, the use of viral-free vectors 
or the omission of c-MYC and KLF-4 drastically reduces reprogramming efficiency, and one 
study found no difference in tumorigenicity between viral and viral-free methods 
www.intechopen.com
 Liver Transplantation – Technical Issues and Complications 
 
160 
(Moriguchi et al., 2010). More recently described epigenetic factors such as cell memory and 
genetic imprinting may also contribute to the tumorigenicity of iPSC, which is not yet 
understood (Ben-David & Benvenisty, 2011). 
3.6.1 iPSC for disease modeling, hepatic differentiation, and transplantation 
Now that iPSC technology has been well established, disease-specific iPSC to model 
diseases in vitro and in vivo may help researchers better understand diseases in order to 
develop new treatments. Park et al. (2008b) described the generation of iPSC from a variety 
of inherited diseases, such as Huntington’s, Duchene’s and Beckers’s muscular dystrophy, 
diabetes mellitus type 1, Down’s syndrome, and Parkinson’s. iPSC have also been generated 
from inherited metabolic disease patients with A1AT, Crigler-Najjar, tyrosinemia type 1, 
familial hypercholesterolemia, and glycogen storage disease type 1a (Rashid et al., 2010), 
which were then differentiated into hepatocytes to more accurately model the disease in 
vitro. More recently, iPSC-derived hepatocyte-like cells generated from the dermal 
fibroblasts of a Wilson’s disease patient was shown to mimic the disease phenotype in vitro 
(Zhang et al., 2011). Importantly, iPSCs of metabolic disease could be genetically corrected 
in culture, differentiated into hepatocytes possessing the ability to make normal protein, and 
potentially infused back into patients to cure their disease. The use of autologous cells 
would also reduce the risk of immune issues and rejection theoretically avoiding the need 
for immunosuppression. Human artificial chromosome technology was used to deliver the 
entire dystrophin gene to genetically correct patient fibroblasts with Duchenne muscular 
dystrophy in vitro, and iPSC were generated from the corrected cells (Kazuki et al., 2010). In 
addition, iPSC-derived hepatocyte-like cells modeling Wilson’s disease were corrected in vitro 
using either lentiviral gene therapy or treatment of the drug curcumin (Zhang et al., 2011). 
 
Fig. 3. Examples of iPSC in vitro. A. undifferentiated iPS cell colony; B. a spontaneously 
differentiating iPS cell colony; C. iPS cell-derived hepatocytes formed after following an in 
vitro protocol adapted from Si-Tayeb et al. 2010. All cells were cultured on matrigel in 
mTeSR1 media 
Using established differentiation protocols for ESCs, researchers have been able to 
differentiate iPSCs into all three germ layers in culture, further proving these cells are truly 
pluripotent. Figure 3 shows examples of cultured iPSC in either an undifferentiated state 
(Figure 3A) or spontaneous differentiation (Figure 3B). Furthermore, there are several 
reports of differentiation of iPSC along a hepatic lineage (Figure 3C) using ESC protocols 
(Si-Tayeb et al., 2010; Song et al., 2009; Liu et al., 2011). However, in most reported cases 
iPSC-derived hepatocytes displayed very low hepatic function and gene expression in vitro 
when compared to primary hepatocytes. However, blastocysts from tyrosinema type 1 
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mouse models deficient in the FAH gene were injected with MEF-derived iPSC, and 
resulting pups with high chimerism could survive without NTBC drug (Espejel et al., 2010). 
FAH-negative pups with low levels of chimerism were dependent on NTBC to survive. 
These data demonstrate the potential for iPSC to form “mature” hepatocytes which can 
express sufficient levels of protein to correct a metabolic defect. However, Espejel et al. 
differentiated iPSC through injection into a blastocyst. As with other stem cells, improved in 
vitro differentiation protocols are needed to yield high amounts of therapeutically useful 
cells.  
3.6.2 Benefits / concerns of iPS cells 
Similar to ESC, the major benefits of iPSC are their self-renewal abilities and differentiation 
potential. iPSC could theoretically provide an unlimited pluripotent source of cells that 
could be banked and differentiated into hepatocytes for transplant when needed. Nakatsuji 
et al. (2008) estimated that an iPSC bank with only 30 stem cell lines could match the HLA 
haplotypes in >80% of the Japanese population. Unlike ESC, patient specific iPSC could be 
generated, corrected, and infused back into a patient avoiding immune problems and the 
need for immunosuppression. Importantly, there are no religious, ethical, or political 
controversies associated with the use of iPSCs. However, the field of iPSC research is very 
new and there are still a lot of unknowns. The major concern with iPSC use is a question of 
safety; iPSC have a high risk of tumorigenicity. Just like ESC, iPSC exhibit genetic instability, 
express TERT, and can produce teratomas in vivo. Furthermore, rapidly accumulating 
evidence suggests these two cell types have important genetic and epigenetic differences 
that influence their tumorigenicity, and that iPSC are likely more tumorigenic than ESC 
(reviewed by Ben-David & Benvenisty, 2011). Furthermore, the most reliable, reproducible, 
and efficient method to currently generate iPSC is through an integrating viral vector 
process that could induce cancers, and both integrating and non-integrating methods use 
reprogramming factors that are highly expressed in many tumor samples. Aside from the 
issue of safety, cell differentiation protocols and methods to enhance engraftment have not 
yet been optimized, and it is currently unknown whether long term survival of iPSCs in vivo 
is possible. Further research is needed to generate iPSC that are safe, effective, and 
therapeutically useful before these cells can be used for clinical cell therapies.  
4. Conclusions 
Alternatives to OLT must be found in order to circumvent the increasing amount of patient 
deaths due to long organ wait times and insufficient numbers of available livers. CTx has 
shown a great deal of promise, and the progress made over the past several decades of 
preclinical and clinical studies provides a growing amount of rationale for its use to treat a 
variety of liver disorders. Cells isolated from donor livers have been proven to provide safe 
and effective liver support for both short- and long-term function. There have been several 
reported clinical cases of disease reversal in acute liver failure, and HTx has provided partial 
correction for a variety of inherited metabolic diseases (Table 1). In vitro gene modification 
to correct allogenic hepatocytes is also possible to avoid immunogenicity of transplanted 
cells and a lifelong immunosuppression regimen. However, complete correction of a 
metabolic disorder by HTx has not yet been achieved, and more than one treatment would 
likely be required to sustain a patient through his/her lifetime. There are still several  
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challenges to overcome. For HTx, the first major challenge is the availability of donor livers 
for the isolation of hepatocytes. There are not enough donor livers rejected for OLT, thus 
making them available for HTx, to provide for everyone requiring treatment. The second is 
regarding reliable storage of isolated hepatocytes. Current cryopreservation and thawing 
protocols result in massive cell loss and decreased viability; this reduces the number of cells 
available for transplant, and cell quality influences cell engraftment, cell function, and thus 
patient outcome. These drawbacks emphasize our need for alternative cell sources. Research 
to use stem cells and stem-like cells (e.g. ESC, MSC, AE, iPSC) for CTx are currently in 
preclinical and, for some, early clinical stages. Though there have been some advances made 
in animal models, the safety and efficacy of these cells must be unequivocally determined. 
All the aforementioned alternative cell types display varying levels of immunomodulatory 
properties making them potentially less immunogenic than hepatocytes. However, ESC, 
MSC, and iPSC all have tumorigenicity risks associated with their use in vivo. It has been 
suggested that more complete differentiation of cells into hepatocyte-like cells may reduce 
tumor formation, though it is not known whether this strategy will completely ablate the 
risk. In addition, the recently discovered epigenetic factors in iPSC must be more thoroughly 
investigated. These epigenetic differences may influence differentiation efficiencies, and it 
has been suggested that they may make iPSC more tumorigenic than ESC (Ben-David & 
Benvenisty, 2011). AE cells are nontumorigenic in both an undifferentiated and 
differentiated state, are nonimmunogenic, and have been used in clinical studies for more 
than sixty years without immunosuppression and without evidence of acute rejection. AE 
cells are clearly the safest alternative to hepatocytes from the stem cells discussed in this 
chapter, but their effectiveness to correct liver disease is currently unknown.   
In summary, considerable progress has been gained in cell transplantation thus far, though 
future work is required to enhance utility of this novel branch of regenerative medicine.  
Improvement of cell engraftment remains the single biggest challenge to overcome. New 
methods to modulate the immune reaction and relieve changes in vascular pressures after 
cell transplant are currently being investigated to enhance engraftment and improve patient 
outcome. Preconditioning protocols of the recipient liver, such as hepatic irradiation, portal 
vein embolization, and surgical resection, may also help to improve engraftment by giving 
donor cells selected growth advantage (Soltys et al., 2010; Puppi et al., 2011), which will be 
of particular importance in patients of metabolic disease. Though hepatocytes remain the 
most preferred cell for cell transplantation, stem cells may provide a useful cell alternative 
to hepatocytes once the question of safety has been resolved and the ability to provide 
therapeutically useful cells at a scale suitable for transplantation is achieved. 
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